Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab

Maureen A. Mealy, Michael Levy

Research output: Contribution to journalArticlepeer-review

Abstract

Neuromyelitis optica is a severe autoimmune condition affecting the central nervous system characterized by a relapsing disease course. Rituximab is a chimeric monoclonal antibody against the protein CD20, and is one of the most utilized medications for management of this disease. A known complication of rituximab use is neutropenia. We report on two patients who developed symptomatic early-onset rituximab-induced agranulocytosis who safely received granulocyte colony-stimulating factor. Neutrophil counts recovered quickly and both patients continue to receive rituximab without further incident.

Original languageEnglish (US)
Pages (from-to)29-30
Number of pages2
JournalJournal of Neuroimmunology
Volume287
DOIs
StatePublished - Oct 15 2015

Keywords

  • Agranulocytosis
  • G-CSF
  • NMO
  • Neuromyelitis optica
  • Neutropenia
  • Rituximab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab'. Together they form a unique fingerprint.

Cite this